Biogen (BIIB) Non-Current Deferred Tax Liability (2009 - 2026)

Biogen (BIIB) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with $483.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 262.99% year-over-year to $483.5 million; the TTM figure through Mar 2026 stood at $483.5 million (up 262.99% YoY), while the FY2025 annual figure was $507.6 million, up 166.46% from the prior year.
• Non-Current Deferred Tax Liability came in at $483.5 million for Q1 2026 at Biogen, down from $507.6 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $882.4 million in Q3 2024, with the low at $118.3 million in Q2 2025.
• Average Non-Current Deferred Tax Liability over 5 years is $435.5 million, with a median of $480.6 million recorded in 2022.
• Across the five-year window, Non-Current Deferred Tax Liability jumped 310.42% in 2024 and sank 79.97% in 2025, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $334.7 million in 2022, then soared by 91.75% to $641.8 million in 2023, then slumped by 70.32% to $190.5 million in 2024, then surged by 166.46% to $507.6 million in 2025, then declined by 4.75% to $483.5 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $483.5 million, $507.6 million, and $358.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.